MedTrace Logo

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

NCT02744209 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2019-11-07

No results posted yet for this study

Summary

This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treated with Pembrolizumab.

Conditions

  • Stage IV Melanoma

Sponsors & Collaborators

Principal Investigators

  • Larry R Pease, Ph.D. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02744209 on ClinicalTrials.gov